Prescription psychostimulants, such as amphetamines and methylphenidate, are primarily used to treat ADHD. Between 2019 and 2022, there was a significant increase in adult prescriptions, particularly among women aged 35 to 64, who experienced a 41% rise. Misuse of these medications was reported in 25% of adults prescribed them, with a notable 9% developing psychostimulant use disorder (PSUD). PSUD is diagnosed based on specific criteria from the DSM-5, indicating serious complications arising from misuse and dependence on these medications.
The use of prescription psychostimulants by adults increased between 2019 and 2022, with 35-to-64-year-old women experiencing the largest increase of 41 percent.
Misuse of prescription psychostimulants occurred in 25 percent of adults prescribed these medications, indicating a significant rate of non-compliant behavior among users.
Among those prescribed psychostimulants, 9 percent developed psychostimulant use disorder (PSUD), reflecting a notable association between prescription and disorder development.
Data from the IQVIA Total Patient Tracker and the National Prescription Audit indicate growing trends in both the prescription and misuse of psychostimulants among adults.
Collection
[
|
...
]